7/15/2022 12:46:33 PM - Slumped well below its 200 DMA line with 5 consecutive losses. Recently met resistance near its 50 DMA line. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
7/14/2022 12:34:11 PM - Slumping further below its 200 DMA line again with today's 5th consecutive loss. Recently met resistance near its 50 DMA line. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
7/13/2022 12:43:20 PM - Slumping further below its 200 DMA line again with today's 3rd consecutive loss. Recently met resistance near its 50 DMA line. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
7/8/2022 12:29:56 PM - Sputtering below its 200 DMA line again after meeting resistance near its 50 DMA line. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
6/15/2022 12:23:07 PM - Met resistance near its 50 DMA line recently and violated its 200 DMA line with damaging volume-driven losses. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
6/13/2022 12:33:06 PM - Met resistance near its 50 DMA line and it is retesting its 200 DMA line. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
6/10/2022 12:17:20 PM - Slumped below its 50 DMA line retesting its 200 DMA line. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
5/27/2022 12:33:53 PM - Slumping back below its 50 DMA line ($44.52) with today's 3rd consecutive loss with above average volume. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
5/26/2022 2:31:55 PM - Consolidating near its 50 DMA line ($44.51). Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
5/23/2022 12:26:15 PM - Consolidating above its 50 DMA line ($44.32). Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
5/20/2022 12:11:06 PM - Sputtering near its 50 DMA line ($44.22). Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
5/19/2022 12:19:22 PM - Slumped below its 50 DMA line ($44.15) again after rebounding with quiet gains this week. UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines.
5/11/2022 12:30:13 PM - Recently slumped below its 50 DMA line ($43.83). UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines.
5/10/2022 12:41:25 PM - UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines.